Máj- és epeúti rák: vizsgálatok itt: Kína
621 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleMDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
- Where
- Fuzhou, Guangzhou, Hangzhou, Hefei, Henan, Jinan, Nanjing, Shanghai
- Életkor
- 18 év to 80 év
- People
- 40
- Run by
- Suzhou Mednovo Yi Medical Technology Co., Ltd.
See details and how to joinNCT07391839 - 1. fázisTaking peopleA Study of SH009 Injection in Patients With Advanced Solid Tumors.
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 150
- Run by
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
See details and how to joinNCT07390838 - 1. fázisTaking peopleA Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 194
- Run by
- Hefei TG ImmunoPharma Co., Ltd.
See details and how to joinNCT07376707 - 3. fázisTaking peopleA Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 604
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07229625 - No phaseNot yet taking people in KínaA Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
- Where
- Ningbo
- Életkor
- 16 év and over
- People
- 300
- Run by
- Ningbo Medical Center Lihuili Hospital
See details and how to joinNCT07368023 - 1. fázisTaking peopleFirst in Human Study of SIM0610 in Solid Tumors
- Where
- Chongqing, Harbin, Jinan, Shanghai, Shenyang
- Életkor
- 18 év and over
- People
- 260
- Run by
- Jiangsu Simcere Pharmaceutical Co., Ltd.
See details and how to joinNCT07348211 - 2. fázisNot yet taking people in KínaDrug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 56
- Run by
- Eastern Hepatobiliary Surgery Hospital
See details and how to joinNCT07363356 - 1. fázisTaking peopleA Phase I Study of CREPT-618 in Locally Advanced HCC
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 13
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07364357 - No phaseTaking peopleA Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 12
- Run by
- Zhejiang University
See details and how to joinNCT07039201 - No phaseTaking peopleLaryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
- Where
- Hangzhou
- People
- 1200
- Run by
- Zhejiang University
See details and how to joinNCT07359586 - 1. fázisTaking peopleA Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
- Where
- Hangzhou, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 72
- Run by
- Zhejiang University
See details and how to joinNCT05155189 - Korai 1. fázisTaking peopleTC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT07242417 - 3. fázisNot yet taking people in KínaNanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
- Where
- Chengdu
- Életkor
- 18 év to 85 év
- People
- 68
- Run by
- Changchun GeneScience Pharmaceutical Co., Ltd.
See details and how to joinNCT07356037 - No phaseTaking peopleClinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer
- Where
- Anyang, Beijing, Ganzhou, Gongzhuling, Guiyang, Hefei, Lishui, Luoyang, Nanchang, Nanning, Shijiazhuang, Taiyuan, Wenzhou, Yichang, Zhengzhou
- Életkor
- 18 év to 80 év
- People
- 216
- Run by
- JIANGSU SHENMING Medical Technology CO., Ltd
See details and how to joinNCT07356531 - 2. fázisNot yet taking people in KínaFAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 86
- Run by
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07314372 - 2. fázisNot yet taking people in KínaTACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
- Where
- Fuzhou, Jinan, Nanning, Qingdao, Taihe, Wuhan
- Életkor
- 18 év to 75 év
- People
- 78
- Run by
- Tongji Hospital
See details and how to joinNCT07350070 - No phaseNot yet taking people in KínaPredictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 276
- Run by
- Tongji Hospital
See details and how to joinNCT07350824 - 2. fázisNot yet taking people in KínaSintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
- Where
- Jinan
- Életkor
- 18 év to 75 év
- People
- 110
- Run by
- Lei ZHAO
See details and how to joinNCT07352007 - Korai 1. fázisNot yet taking people in KínaHead to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 150
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07352345 - 2. fázisNot yet taking people in KínaFOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 36
- Run by
- Sun Yat-sen University
See details and how to joinNCT07353827 - 2. fázisTaking peopleSintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 37
- Run by
- Sun Yat-sen University
See details and how to joinNCT07324824 - No phaseTaking peopleConversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
- Where
- Nanning
- Életkor
- 18 év to 75 év
- People
- 2000
- Run by
- Guangxi Medical University
See details and how to joinNCT06405321 - 2. fázisTaking peopleQL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 38
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07327788 - No phaseNot yet taking people in KínaA Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 193
- Run by
- Eastern Hepatobiliary Surgery Hospital
See details and how to joinNCT07337031 - 2. fázisTaking peopleEfcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
- Where
- Yangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Northern Jiangsu People's Hospital
See details and how to joinNCT07337421